BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 25500824)

  • 1. Evaluation of a nonpeptidic ligand for imaging of cholecystokinin 2 receptor-expressing cancers.
    Wayua C; Low PS
    J Nucl Med; 2015 Jan; 56(1):113-9. PubMed ID: 25500824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of a cholecystokinin 2 receptor-targeted near-infrared dye for fluorescence-guided surgery of cancer.
    Wayua C; Low PS
    Mol Pharm; 2014 Feb; 11(2):468-76. PubMed ID: 24325469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [
    Kaloudi A; Kanellopoulos P; Radolf T; Chepurny OG; Rouchota M; Loudos G; Andreae F; Holz GG; Nock BA; Maina T
    Mol Pharm; 2020 Aug; 17(8):3116-3128. PubMed ID: 32568549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
    Béhé M; Behr TM
    Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of a Neurokinin-1 Receptor-Targeted Technetium-99m Conjugate for Neuroendocrine Cancer Imaging.
    Kanduluru AK; Srinivasarao M; Wayua C; Low PS
    Mol Imaging Biol; 2020 Apr; 22(2):377-383. PubMed ID: 31292915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multifactorial diagnostic NIR imaging of CCK2R expressing tumors.
    Kossatz S; Béhé M; Mansi R; Saur D; Czerney P; Kaiser WA; Hilger I
    Biomaterials; 2013 Jul; 34(21):5172-80. PubMed ID: 23591397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiolabeled gastrin/CCK analogs in tumor diagnosis: towards higher stability and improved tumor targeting.
    Kaloudi A; Nock BA; Krenning EP; Maina T; De Jong M
    Q J Nucl Med Mol Imaging; 2015 Sep; 59(3):287-302. PubMed ID: 26158215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo characterization of three 68Ga- and 111In-labeled peptides for cholecystokinin receptor imaging.
    Roosenburg S; Laverman P; Joosten L; Eek A; Rutjes FP; van Delft FL; Boerman OC
    Mol Imaging; 2012; 11(5):401-7. PubMed ID: 22954184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT.
    Gainkam LO; Huang L; Caveliers V; Keyaerts M; Hernot S; Vaneycken I; Vanhove C; Revets H; De Baetselier P; Lahoutte T
    J Nucl Med; 2008 May; 49(5):788-95. PubMed ID: 18413403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of cholecystokinin 2 receptor (CCK2R) in neoplastic tissue.
    Roy J; Putt KS; Coppola D; Leon ME; Khalil FK; Centeno BA; Clark N; Stark VE; Morse DL; Low PS
    Oncotarget; 2016 Mar; 7(12):14605-15. PubMed ID: 26910279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stabilized (111)in-labeled sCCK8 analogues for targeting CCK2-receptor positive tumors: synthesis and evaluation.
    Roosenburg S; Laverman P; Joosten L; Eek A; Oyen WJ; de Jong M; Rutjes FP; van Delft FL; Boerman OC
    Bioconjug Chem; 2010 Apr; 21(4):663-70. PubMed ID: 20302291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. (99m)Tc-labeled SWL specific peptide for targeting EphA2 receptor.
    Liu Y; Lan X; Wu T; Lang J; Jin X; Sun X; Wen Q; An R
    Nucl Med Biol; 2014 Jul; 41(6):450-6. PubMed ID: 24768147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DOTA-MGS5, a New Cholecystokinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic Use.
    Klingler M; Summer D; Rangger C; Haubner R; Foster J; Sosabowski J; Decristoforo C; Virgolini I; von Guggenberg E
    J Nucl Med; 2019 Jul; 60(7):1010-1016. PubMed ID: 30530828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting.
    Klingler M; Decristoforo C; Rangger C; Summer D; Foster J; Sosabowski JK; von Guggenberg E
    Theranostics; 2018; 8(11):2896-2908. PubMed ID: 29896292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog
    Sauter AW; Mansi R; Hassiepen U; Muller L; Panigada T; Wiehr S; Wild AM; Geistlich S; Béhé M; Rottenburger C; Wild D; Fani M
    J Nucl Med; 2019 Mar; 60(3):393-399. PubMed ID: 30002107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholecystokinin-B/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential.
    Behr TM; Béhé M; Angerstein C; Gratz S; Mach R; Hagemann L; Jenner N; Stiehler M; Frank-Raue K; Raue F; Becker W
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3124s-3138s. PubMed ID: 10541353
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.